This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Stryker (SYK) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
by Zacks Equity Research
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
by Zacks Equity Research
Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View
by Zacks Equity Research
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Is the Options Market Predicting a Spike in Athira Pharma (ATHA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
Athira Pharma, Inc. (ATHA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) closed at $10.13 in the latest trading session, marking a -1.65% move from the prior day.
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
Athira Pharma, Inc. (ATHA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) closed the most recent trading day at $10.06, moving +1.51% from the previous trading session.
Athira Pharma, Inc. (ATHA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) closed the most recent trading day at $10.04, moving -1.47% from the previous trading session.
Implied Volatility Surging for Athira Pharma (ATHA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
Athira Pharma, Inc. (ATHA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.